Menu Search
Equities

Assertio Holdings Inc

ASRT:NAQ

Assertio Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.35
  • Today's Change0.05 / 3.85%
  • Shares traded517.58k
  • 1 Year change-49.06%
  • Beta0.7860
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Assertio Holdings Inc had net income fall from a gain of 109.63m to a loss of 331.94m despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
Gross margin72.12%
Net profit margin-261.08%
Operating margin-203.16%
Return on assets-100.82%
Return on equity-178.62%
Return on investment-134.56%
More ▼

Cash flow in USDView more

In 2023, Assertio Holdings Inc increased its cash reserves by 13.09%, or 8.50m. The company earned 49.60m from its operations for a Cash Flow Margin of 32.62%. In addition the company generated 3.10m cash from investing, though they paid out 44.20m more in financing than they received.
Cash flow per share-3.46
Price/Cash flow per share--
Book value per share1.39
Tangible book value per share0.3474
More ▼

Balance sheet in USDView more

Assertio Holdings Inc has a Debt to Total Capital ratio of 22.66%, a higher figure than the previous year's 15.04%.
Current ratio1.93
Quick ratio1.51
Total debt/total equity0.2931
Total debt/total capital0.2266
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.